1,1-dimethylethyl 9-cyano-5-[3-(methyloxy)-3-oxopropyl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate | 1165946-79-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶嗪类
• 英文名称: 1,1-dimethylethyl 9-cyano-5-[3-(methyloxy)-3-oxopropyl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate
• 英文别名: tert-butyl 9-cyano-5-(3-methoxy-3-oxopropyl)-3,5-dihydro-2H-1,4-benzoxazepine-4-carboxylate
• CAS: 1165946-79-1
• 化学式: C₁₉H₂₄N₂O₅
• 分子量: 360.41
• InChiKey: AORFTERWVIAFFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  88.9
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  1,1-dimethylethyl 9-cyano-5-[3-(methyloxy)-3-oxopropyl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate 在 盐酸羟胺 、 碳酸氢钠 、 三乙胺 作用下， 以 甲醇 、 乙腈 为溶剂， 反应 97.0h， 生成 1,1-dimethylethyl 9-(5-{3-chloro-4-[(1-methylethyl)oxy]phenyl}-1,2,4-oxadiazol-3-yl)-5-[3-(methyloxy)-3-oxopropyl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate
  参考文献：
  名称：

  Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles

  摘要：

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.

  DOI：

  10.1021/jm5010336
• 作为产物：
  描述：

  1,1-dimethylethyl 9-cyano-5-[3-(methyloxy)-2-propen-1-yl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 为溶剂， 反应 64.0h， 以56%的产率得到1,1-dimethylethyl 9-cyano-5-[3-(methyloxy)-3-oxopropyl]-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate
  参考文献：
  名称：

  Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles

  摘要：

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.

  DOI：

  10.1021/jm5010336

文献信息

• [EN] 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] COMPOSÉS DE 1,2,4-OXADIAZOLE POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES
  申请人：GLAXO GROUP LTD

  公开号：WO2009080730A1

  公开（公告）日：2009-07-02

  The present invention relates to novel oxadiazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof thereof. Compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of conditions or disorders which are mediated via the S1 P1 receptor. In particular the compounds of formula (I) and their pharmaceutically acceptable salts are of use in the treatment of multiple sclerosis, autoimmune diseases, chronic inflammatory disorders, asthma, inflammatory neuropathies, arthritis, transplantation, Crohn's disease, ulcerative colitis, lupus erythematosis, psoriasis, ischemia-reperfusion injury, solid tumours, and tumour metastasis, diseases associated with angiogenesis, vascular diseases, pain conditions, acute viral diseases, inflammatory bowel conditions, insulin and non-insulin dependant diabetes.

  本发明涉及公式(I)的新型噁二唑衍生物或其药学上可接受的盐。公式(I)化合物及其药学上可接受的盐可用于治疗通过S1 P1受体介导的疾病或紊乱。特别是公式(I)化合物及其药学上可接受的盐可用于治疗多发性硬化症、自身免疫疾病、慢性炎症性疾病、哮喘、炎性神经病、关节炎、移植、克罗恩病、溃疡性结肠炎、红斑狼疮、银屑病、缺血再灌注损伤、实体肿瘤、肿瘤转移、与血管生成相关的疾病、血管疾病、疼痛症状、急性病毒性疾病、炎症性肠病、胰岛素依赖和非依赖性糖尿病。
• 1, 2, 4 -OXADIAZOLE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
  申请人：Heer Jag Paul

  公开号：US20100273770A1

  公开（公告）日：2010-10-28

  The present invention relates to novel oxadiazole derivatives having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.

  本发明涉及具有药理活性的新型噁唑二氮杂环衍生物，其制备过程，包含它们的制药组合物以及它们在治疗各种疾病中的应用。
• Optimization of Sphingosine-1-phosphate-1 Receptor Agonists: Effects of Acidic, Basic, and Zwitterionic Chemotypes on Pharmacokinetic and Pharmacodynamic Profiles
  作者：John Skidmore、Jag Heer、Christopher N. Johnson、David Norton、Sally Redshaw、Jennifer Sweeting、David Hurst、Andrew Cridland、David Vesey、Ian Wall、Mahmood Ahmed、Dean Rivers、James Myatt、Gerard Giblin、Karen Philpott、Umesh Kumar、Alexander Stevens、Rino A. Bit、Andrea Haynes、Simon Taylor、Robert Watson、Jason Witherington、Emmanuel Demont、Tom D. Heightman

  DOI：10.1021/jm5010336

  日期：2014.12.26

  The efficacy of the recently approved drug fingolimod (FTY720) in multiple sclerosis patients results from the action of its phosphate metabolite on sphingosine-1-phosphate S1P(1) receptors, while a variety of side effects have been ascribed to its S1P(3) receptor activity. Although S1P and phospho-fingolimod share the same structural elements of a zwitterionic headgroup and lipophilic tail, a variety of chemotypes have been found to show S1P(1) receptor agonism. Here we describe a study of the tolerance of the S1P(1) and S1P(3) receptors toward bicyclic heterocycles of systematically varied shape and connectivity incorporating acidic, basic, or zwitterionic headgroups. We compare their physicochemical properties, their performance in in vitro and in vivo pharmacokinetic models, and their efficacy in peripheral lymphocyte lowering. The campaign resulted in the identification of several potent S1P(1) receptor agonists with good selectivity vs S1P(3) receptors, efficacy at <1 mg/kg oral doses, and developability properties suitable for progression into preclinical development.